Follow-up Cystoscopy Schedule for Low-Grade Superficial Bladder TCC

Initial Surveillance Strategy

• The National Comprehensive Cancer Network (NCCN) recommends the first follow-up cystoscopy to occur at 3-4 months after initial transurethral resection (TURBT) 1, 2, 3
• If the initial surveillance cystoscopy is negative, the risk stratification fundamentally changes and allows for extended intervals 1

Extended Follow-up Schedule After Negative Initial Cystoscopy

• Following a negative cystoscopy at 3-4 months, the next cystoscopy should be performed at 6-9 months (total of 9-12 months from initial TURBT) 1
• Subsequently, cystoscopy should be performed yearly for up to 5 years 1
• After 5 years, cystoscopy should only be performed based on clinical indication (symptoms, positive cytology, or other concerning findings) 1

Important Distinction: What Defines "Low-Risk"

• Low-risk disease is specifically defined as Stage Ta (non-invasive papillary carcinoma) 1
• Low-risk disease is also defined as low-grade histology 1
• Typically, low-risk disease is characterized by solitary tumors <3 cm 4
• Low-risk disease is characterized by no carcinoma in situ (CIS) 4

Role of Urinary Cytology

• The NCCN recommends that urinary cytology is NOT routinely used for low-grade Ta tumors during surveillance 1
• Cytology should be reserved for high-risk disease (high-grade Ta, T1, or CIS) 1, 5

Upper Tract Imaging

• Beyond baseline imaging, upper tract imaging is NOT indicated for patients with low-risk non-muscle-invasive bladder cancer unless symptoms develop 1
• This contrasts sharply with high-risk disease, where upper tract imaging every 1-2 years is recommended 1, 5

Critical Pitfalls to Avoid

• The 2020 NCCN guidelines explicitly liberalized surveillance for low-risk disease, and older guidelines (2009) should not be applied 1, 5, 2, 3
• If any recurrence is detected, the patient should undergo repeat TURBT and be restratified based on the pathology of the recurrent tumor 1

What to Do If Recurrence is Detected

• Perform repeat TURBT to completely resect visible disease 1
• Consider single immediate postoperative intravesical chemotherapy (within 24 hours) for recurrent low-grade Ta disease 2, 3
• For patients with history of multiple recurrences, a 6-week induction course of intravesical chemotherapy may be warranted 2
• BCG is NOT indicated for low-grade Ta tumors and should be reserved for high-grade disease 1, 2

NCCN 2020 Guidelines for Surveillance of Low‑Risk Non‑Muscle‑Invasive Bladder Cancer

Confirmation of Complete Resection

• In patients with low‑grade Ta bladder cancer, a complete resection is defined as the absence of residual tumor on an immediate repeat TURBT (re‑TURBT) 6.

Recommended Surveillance Cystoscopy Schedule

• For low‑risk disease, the first surveillance cystoscopy should be performed 3–4 months after the initial TURBT; if this cystoscopy is negative, the next examination is scheduled at 6–9 months (total 9–12 months from TURBT) 6.
• After a negative cystoscopy at 6–9 months, surveillance cystoscopy is then performed yearly for up to 5 years 6.
• Beyond 5 years, cystoscopy is performed only when clinically indicated (e.g., new hematuria or other concerning symptoms) 6.

Adjunctive Laboratory Testing

• Routine urinary cytology is not recommended during surveillance of low‑grade Ta tumors; cytology should be reserved for high‑grade disease (high‑grade Ta, T1, or CIS) 6.

Imaging Recommendations

• Upper‑tract imaging beyond the baseline study is not indicated for low‑risk non‑muscle‑invasive bladder cancer unless the patient develops relevant symptoms 6.
• In contrast, high‑risk disease requires upper‑tract imaging every 1–2 years 6.

Management of Detected Recurrence

• If a recurrence is identified at any surveillance visit, a repeat TURBT should be performed to achieve complete resection of the visible lesion 6.
• After resection of a recurrent tumor, the patient should be re‑stratified according to the pathology of the new specimen 6.